DePuy Synthes Brand Guidelines: Warsaw Splints, a Swiss Trademark & a Planned Spin-Off

A travelling salesman and a fibre splint.

DePuy Synthes is two histories joined in 2012. The older half begins in Warsaw, Indiana, in 1895, when Revra DePuy, a travelling salesman who had settled in the town, founded DePuy Manufacturing to make fibre splints for setting broken bones. Medical Device Network, in a 2021 history marking the company’s 125th year, describes the splints as an alternative to the improvised wooden barrel-stave splints then in use, moulded at first on DePuy’s own limbs, and calls the firm the world’s first commercial orthopaedic company. For its first five years the business ran from the Hayes Hotel in Warsaw; a factory followed, and the range grew to slings, neck collars and braces.

One early employee shaped the town’s future. Justin Zimmer was on the payroll by 1919 and rose to national sales manager; in 1926, after his offer to buy DePuy was turned down, he started a rival company in Warsaw, the business now known as Zimmer Biomet, Medical Device Network reported. The same article says Warsaw is now hailed as the orthopaedics capital of the world, and that DePuy Synthes’ joint reconstruction business is still based there.

DePuy then changed owners several times. Investors at Brown Brothers Harriman of New York bought it in 1965; the blood diagnostics company Bio-Dynamics acquired it in 1968, a deal centred on exclusive rights to market a hip replacement invented by Maurice Müller; and in 1974 it was sold to Boehringer Mannheim, then owned by Corange. Under that owner it worked with the surgeon Charles Engh on an artificial hip that relied on the patient’s own tissue rather than cement to hold it, added the British firm Thackray in 1990 and the trauma specialist ACE Medical in 1994, and moved into spinal implants through a partnership with Biedermann Motech of Germany, Medical Device Network reported.

Johnson & Johnson, and a Swiss half.

In 1998 DePuy bought AcroMed, a spinal implant maker, and was renamed DePuy AcroMed. The same year, after Roche had acquired Corange in 1997, Johnson & Johnson bought DePuy and merged its own orthopaedic business into it, Medical Device Network reported. English Wikipedia records that J&J opened a production site in Suzhou, China, in 2008 that serves DePuy among other J&J companies.

The other half began in Switzerland. English Wikipedia says Synthes started in 1960 as a trademark of the AO/ASIF, the Swiss Arbeitsgemeinschaft für Osteosynthesefragen, an association for the study of internal fracture fixation, and that the mark was applied to implants made under licence by Straumann and Mathys. In 1975 a third partner joined: Synthes USA, a firm founded by Hansjörg Wyss. Straumann spun its implant business off in 1990 as Stratec Medical, which merged with Synthes USA in 1999 to form Synthes-Stratec; after Mathys sold its osteosynthesis business to the group in 2004, the name was shortened to Synthes. In 2006, Wikipedia says, the company bought the Synthes name and most of the related patents from the AO foundation, and the two kept working together. Synthes was run from Solothurn, Switzerland, and West Chester, Pennsylvania, and made implants for trauma, spine and craniomaxillofacial surgery as well as surgical power tools.

Both halves carry recorded setbacks. DePuy launched its ASR hip system in 2005; it withdrew the ASR products from the Australian market in 2009 and recalled them worldwide in 2010, and in 2013 DePuy and J&J agreed to settle about 8,000 ASR lawsuits, Medical Device Network reported. The same publication notes that Synthes and its subsidiary Norian had earlier pleaded guilty in a US case over the sale of a bone void filler for unapproved uses.

How orthopaedic makers present themselves.

Orthopaedic device makers sell to a narrow, expert audience: surgeons, theatre teams, hospital buyers and the distributors who serve them. Their brand material is shaped by that audience. Product imagery tends to be precise and technical, with implants rendered as clean metallic objects, often lit against dark or neutral backgrounds so that the form of a stem, a plate or a screw reads clearly.

Clinical imagery sits alongside the renders. X-rays, bone models, anatomical cut-aways and diagrams of a joint or a spinal segment show where a device goes and how it is meant to fit. Many makers also photograph surgeons in theatre, in gowns and masks under surgical lights, and show the trays of instruments that accompany an implant system, laid out in rows that suggest order and completeness.

Education is a large part of the picture. Device makers run training courses, cadaver labs and online technique guides, and much of their visual output is instructional: step-by-step surgical technique documents, animations and videos. Congresses matter too. Large meetings such as the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) and the congress of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) are where new systems are often shown, on stands designed to carry a brand at scale.

Corporate identities in the field are usually restrained: sans-serif wordmarks, a small set of brand colours and a great deal of white space, with the visual drama left to the product and the clinical image. Many brands also sit inside larger groups, so a single name may appear alongside a parent company’s mark. That makes the typeface, the palette and the treatment of imagery the main tools a maker has for being recognised.

One franchise, a planned separation.

Johnson & Johnson completed its acquisition of Synthes in June 2012 and joined it to DePuy to form the DePuy Synthes Companies; English Wikipedia notes that DePuy’s earlier logo, with its characteristic red dot, changed after the merger. The franchise sold its Codman neurosurgery business to Integra LifeSciences in 2017. Its products since include the ATTUNE knee system, approved in 2011, which DePuy Synthes said in 2020 had reached one million patients, and the VELYS robotic-assisted system, cleared by the FDA in January 2021 for use with ATTUNE, Medical Device Network reported. In September 2023 J&J said its medtech and pharmaceutical segments would unite under the Johnson & Johnson name.

That arrangement is set to change. On October 14, 2025, Johnson & Johnson announced its intent to separate its orthopaedics business into a standalone company “operating as DePuy Synthes,” targeting completion within 18 to 24 months and naming Namal Nawana as worldwide president; J&J said it would keep running the business in line with its current strategy during the process. The DePuy Synthes website presents the business under the line “Humanly Moved” and lists joint reconstruction, trauma, spine and sports medicine among its specialties, alongside the VELYS digital surgery portfolio.

For a design guide, DePuy Synthes shows how one corporate name can carry two very different origins, a small-town splint maker and a Swiss surgeons’ trademark. Compare Johnson & Johnson, its parent, and Zimmer Biomet, its Warsaw neighbour. For this guide we use a deep navy, a signal red and bone white with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep DePuy Synthes’s identity on hand — save it to a board in the Made Good inspiration library.